Triostat

(Liothyronine)

Phase 2Small molecule

VViking Therapeutics, Inc.

Triostat is one of 84 small molecule programs targeting Hypothyroidism. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

HypothyroidismActive, not recruiting

Thyroid CancerActive, not recruiting

Recurrent MedulloblastomaActive, not recruiting

Hypothyroidism PrimaryNot yet recruiting

Brain TumorsTerminated

MedulloblastomaRecruiting

HypothyroidismPreclinical

Active, not recruiting

Thyroid CancerPreclinical

Active, not recruiting

Recurrent MedulloblastomaPhase 2

Active, not recruiting

Hypothyroidism PrimaryPhase 2

Not yet recruiting

Brain TumorsPreclinical

Terminated

MedulloblastomaPhase 2

Recruiting

Competition

Competitive Landscape

65 competitors in Thyroid Cancer

#DrugCompanyPhaseTrials

Tafinlar

Novartis

Approved

11 2

Cabometyx

Bristol-Myers Squibb

Approved

10 3

Keytruda

Merck & Co.

Approved

9 4

Vitrakvi

Bayer

Approved

3 5

Retevmo

Eli Lilly

Approved

3 6

Rozlytrek

Roche

Approved

2 7

Caprelsa

GGenzyme, a Sanofi Company

Approved

10 8

Nexavar

Bayer

Phase 3

12 9

Mekinist

Novartis

Phase 3

8 10

Gavreto

RRigel Pharmaceuticals

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Recurrent Medulloblastoma

NCT04743661

Q4 2027

Phase 2Not yet recruiting

Hypothyroidism Primary

NCT07424183

Q1 2031

PreclinicalRecruiting

Medulloblastoma

NCT07346157

Clinical

Trials by Indication[1]

Heart Failure3 trials

Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF)

Completed·JJens Faber·N/A·NCT01481402·21 enrolled

Developing Oral LT3 Therapy for Heart Failure - HFpEF

Completed·UUniversity of Pennsylvania·Phase 1/2·NCT04111536·28 enrolled

Developing Oral LT3 Therapy for Heart Failure - HFrEF

Completed·UUniversity of Pennsylvania·Phase 1/2·NCT04112316·28 enrolled

Thyroid2 trials

Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients

Completed·AAzienda USL Modena·Phase 2/3·NCT03053115·160 enrolled

Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT02457897·7 enrolled

Cardiovascular Function1 trial

Effects of Liothyronine on Energy Expenditure and Cardiovascular Function

Completed·VVirginia Commonwealth University·Phase 1/2·NCT03098433·22 enrolled

Metabolism1 trial

Energy Metabolism in Thyroidectomized Patients

Completed·VVirginia Commonwealth University·Phase 2·NCT04782856·13 enrolled

Thyroid Cancer1 trial

Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer

Completed·PPatrice Perron·N/A·NCT00223158·70 enrolled

8 more indications

Glioblastoma1 trial

Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma

Withdrawn·EEmory University·Phase 1·NCT05017610

Brain Tumors1 trial

Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors

Terminated·MM.D. Anderson Cancer Center·N/A·NCT00488644·12 enrolled

Bipolar Depression1 trial

Liothyronine (T3) for Bipolar Depression

Completed·NNorthwell Health·Phase 3·NCT00790738·11 enrolled

Hypothyroidism1 trial

Mechanistic Study of Subclinical Hypothyroidism In the Elderly

Completed·UUniversity of Pennsylvania·N/A·NCT02399475·14 enrolled

Medulloblastoma1 trial

PNOC044: Liothyronine (L-T3) in Combination With Bevacizumab, Irinotecan and Temozolomide (BIT) for Progressive or Relapsed Medulloblastoma (Cohort 1) or as Monotherapy for Medulloblastoma With Minimal Residual Disease (Cohort 2)

Recruiting·SSabine Mueller, MD, PhD·Preclinical·NCT07346157·69 enrolled

Hypothyroidism Primary1 trial

T4/T3 Therapy in Hypothyroidism

Not yet recruiting·UUniversity of Pennsylvania·Phase 2·NCT07424183·60 enrolled

Recurrent Medulloblastoma1 trial

Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients With Recurrent Medulloblastoma and Ependymoma

Active, not recruiting·PPediatric Brain Tumor Consortium·Phase 2·NCT04743661·62 enrolled

Unspecified2 trials

Open-label Study of Liothyronine in MS

Completed·JJohns Hopkins University·Phase 1·NCT02506751·20 enrolled

Identification of Non-responders to Levothyroxine Therapy

Completed·OOslo University Hospital·Phase 2·NCT03627611·69 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

CYTOMEL

NDA NDA010379

Dec 31, 1991

TRIOSTAT

NDA NDA020105

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Liothyronine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Liothyronine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Liothyronine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020105). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Viking Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: VViking Therapeutics, Inc.

Triostat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q1 2031

Trials by Indication[1]

Heart Failure3 trials

Thyroid2 trials

Cardiovascular Function1 trial

Metabolism1 trial

Thyroid Cancer1 trial

Glioblastoma1 trial

Brain Tumors1 trial

Bipolar Depression1 trial

Hypothyroidism1 trial

Medulloblastoma1 trial

Hypothyroidism Primary1 trial

Recurrent Medulloblastoma1 trial

Unspecified2 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News